Is MRV.TO undervalued or overvalued?

As of 2025-03-19, the Intrinsic Value of Nuvo Pharmaceuticals Inc (MRV.TO) is 13.23 CAD. This MRV.TO valuation is based on the model Discounted Cash Flows (Growth Exit 10Y). With the current market price of 1.35 CAD, the upside of Nuvo Pharmaceuticals Inc is 880.30%. This means that MRV.TO is undervalued by 880.30%.

The range of the Intrinsic Value is 4.69 - 99.93 CAD

	Range	Selected	Upside
a
DCF (Growth 5y)	(5.54) - 1.75	(4.89)	-462.2%
DCF (Growth 10y)	4.69 - 99.93	13.23	880.3%
DCF (EBITDA 5y)	(3.51) - (1.96)	(1,234.50)	-123450.0%
DCF (EBITDA 10y)	(0.03) - 2.98	1.16	-14.4%
Fair Value	6.65 - 6.65	6.65	392.82%
P/E	7.56 - 16.18	11.41	745.2%
EV/EBITDA	1.82 - 18.84	10.28	661.8%
EPV	35.65 - 38.15	36.90	2633.4%
DDM - Stable	16.78 - 1,522.45	769.62	56908.6%
DDM - Multi	(40.13) - (2,896.65)	(80.02)	-6027.5%